Drug Therapy for Acute Heart Failure
Salvatore Di Somma1, Laura Magrini1
1Emergency Department Sant'Andrea Hospital, Medical-Surgery Sciences and Translational Medicine, University La Sapienza, Rome, Italy.
Revista Espanola De Cardiologia (English Ed.)
|June 20, 2015
Summary
Acute heart failure (AHF) requires better treatments. Current therapies ease symptoms but do not reduce mortality, highlighting the need for new AHF interventions.
Area of Science:
- Cardiology
- Emergency Medicine
- Pharmacology
Background:
- Acute heart failure (AHF) is a leading cause of hospitalization globally.
- Current management focuses on symptom relief and hemodynamic stabilization.
- Existing treatments do not significantly improve short- or long-term mortality rates.
Purpose of the Study:
- To address the unmet need for improved patient outcomes in acute heart failure.
- To explore novel therapeutic strategies beyond current guideline-recommended treatments.
- To stimulate research into more effective acute heart failure interventions.
Main Methods:
- Review of current international guidelines for acute heart failure management.
- Analysis of standard emergency department therapeutic approaches.
- Identification of limitations in existing treatments regarding mortality impact.
Main Results:
- Standard treatments include intravenous diuretics, oxygen, and vasodilators.
- These interventions provide symptomatic relief and improve hemodynamics.
- However, these treatments have not demonstrated a positive impact on mortality.
Conclusions:
- There is a critical need for novel therapeutic agents in acute heart failure.
- Further research is essential to develop treatments that reduce mortality.
- The global research effort in AHF treatment is expanding.
Keywords:
Acute heart failureDrug therapyEmergency departmentHospitalizaciónHospitalizationInsuficiencia cardiaca agudaServicio de urgenciasTratamiento farmacológicoMore Related Videos
09:11Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix
Published on: September 22, 2014
12.5K
07:40Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
Published on: May 26, 2023
1.8K
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.5K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.5K
01:30Heart Failure V: Medical Management
566
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
566
01:22Heart Failure VI: Adjunct Therapies
597
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
597
01:22Heart Failure Drugs: β-Blockers
1.2K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.2K
01:22Heart Failure Drugs: Diuretics
1.2K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.2K
01:26Heart Failure Drugs: Inotropic Agents
1.9K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.9K